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Assessing the effect of interventions for
axial spondyloarthritis according to the
endorsed ASAS/OMERACT core outcome
set: a meta-research study of trials included
in Cochrane reviews
Rikke A. Andreasen1,2 , Lars E. Kristensen2, Xenofon Baraliakos3, Vibeke Strand4, Philip J. Mease5, Maarten de Wit6,
Torkell Ellingsen7, Inger Marie J. Hansen1, Jamie Kirkham8, George A. Wells9, Peter Tugwell10, Lara Maxwell10,
Maarten Boers11, Kenneth Egstrup12 and Robin Christensen2,7*

Abstract
The Assessment of SpondyloArthritis international Society (ASAS) has defined core sets for (i) symptom-modifying
anti-rheumatic drugs (SM-ARD), (ii) clinical record keeping, and (iii) disease-controlling anti-rheumatic therapy (DCART). These include the following domains for all three core sets: “physical function,” “pain,” “spinal mobility,” “spinal
stiffness,” and “patient’s global assessment” (PGA). The core set for clinical record keeping further includes the
domains “peripheral joints/entheses” and “acute phase reactants,” and the core set for DC-ART further includes the
domains “fatigue” and “spine radiographs/hip radiographs.” The Outcome Measures in Rheumatology (OMERACT)
endorsed the core sets in 1998.
Using empirical evidence from axSpA trials, we investigated the efficacy (i.e., net benefit) according to the ASAS/
OMERACT core outcome set for axSpA across all interventions tested in trials included in subsequent Cochrane
reviews. For all continuous scales, we combined data using the standardized mean difference (SMD) to metaanalyze outcomes involving the same domains. Also, through meta-regression analysis, we examined the effect of
the separate SMD measures (independent variables) on the primary endpoint (log [OR], dependent variable) across
all trials.
Based on 11 eligible Cochrane reviews, from these, 85 articles were screened; we included 43 trials with 63
randomized comparisons. Mean (SD) number of ASAS/OMERACT core outcome domains measured for SM-ARD/
physical therapy trials was 4.2 (1.7). Six trials assessed all proposed domains. Mean (SD) for number of core outcome
domains for DC-ART trials was 5.8 (1.7). No trials assessed all nine domains. Eight trials (16%) were judged to have
(Continued on next page)
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inadequate (i.e., high risk of) selective outcome reporting bias. The most responsible core domains for achieving
success in meeting the primary objective per trial were pain, OR (95% CI) 5.19 (2.28, 11.77), and PGA, OR (95% CI)
1.87 (1.14, 3.07). In conclusion, selective outcome reporting (and “missing data”) should be reduced by encouraging
the use of the endorsed ASAS/OMERACT outcome domains in clinical trials. Overall outcome reporting was good
for SM-ARD/physical therapy trials and poor for DC-ART trials. Our findings suggest that both PGA and pain provide
a valuable holistic construct for the assessment of improvement beyond more objective measures of spinal
inflammation.
Keywords: Axial spondyloarthritis, Ankylosing spondylitis, Core outcome set, Meta-analysis

Introduction
Since 1992, the Outcome Measures in Rheumatology
(OMERACT) consensus initiative has successfully developed core—or minimum—sets for many rheumatologic
conditions [1]. A “core outcome set” (COS) represents
which outcome domains (i.e., constructs or concepts
[what to measure]) and outcome measurements (i.e.,
how to measure]) to apply in RCTs [2].
ASAS has aimed to bring evidence-based unity to
the multitude of assessments in the field of axial
spondyloarthritis (axSpA). Currently, ASAS’s scope includes the entire spectrum of SpA [3]. axSpA comprises two subcategories based on the presence of
structural changes in the sacroiliac joints: radiographic (r-) axSpA, implying the fulfillment of the
modified New York criteria, and non-radiographic
(nr) axSpA.
ASAS has selected a set of core outcome domains
to include among a set of standardized measures in
clinical trials, which is defined by the following scenarios: (i) symptom-modifying anti-rheumatic drugs
(SM-ARD)/physiotherapy, (ii) clinical record keeping
for studies, and (iii) disease-controlling anti-rheumatic
therapy (DC-ART) (Fig. 1). The selected domains to
include as standardized outcomes in RCTs for all
three scenarios include the following: “physical function,” “pain,” “spinal mobility,” “spinal stiffness,” and
“patient’s global assessment” (PGA). The core set for
clinical record keeping further includes the domains
“peripheral joints/entheses” and “acute phase reactants,” and the core set for DC-ART further includes
the domains “fatigue” and “spine and hip radiographs”
[4]. ASAS core outcome domain sets were endorsed
by OMERACT in 1998 [5].
Although composite outcomes seem an attractive
method to increase statistical power (e.g., BASDAI 50
response), they can mask the effect of (or absence of)
the individual domains of treatment. This study therefore sets out to assess the effect of interventions for
axSpA according to each core domain in the existing
COS, as well as its association with the primary statistical outcome in the individual trials.

Main text
Materials and methods

We conducted a meta-epidemiological study by evaluating axSpA trials included in Cochrane reviews (i.e.,
Cochrane Musculoskeletal Review Group). Study selection, assessment of eligibility criteria, data extraction, and statistical analyses were performed based on
a pre-specified protocol. In accordance with current
methodology, the protocol is available (Supplement A)
and registered on PROSPERO (CRD42018091257).
The study conforms to the Preferred Reporting Items
for Systematic Reviews and Meta-Analyses (PRISMA)
guidelines for reporting systematic reviews and metaanalyses [6, 7].
Literature search

A systematic search was done on May 1, 2018, to
identify all Cochrane reviews that reported interventions for the management of axSpA. Two reviewers
(RAA and RC) searched directly in the Cochrane
Database of Systematic Reviews, where eligible trials
were identified from published Cochrane reviews (i.e.,
meta-analyses) after a thorough search, using the following terms: (ankylosing spondylitis OR bechterew
disease OR ankylosing spondylarthritides OR axial
spondyloarthritis OR axial spondyloarthritides). The
most recent version of the Cochrane review was used.
Unlike what was pre-specified in PROSPERO, for
feasibility, we used the Cochrane Database of Systematic Reviews directly rather than PubMed, since this
meta-research study’s eligibility criteria state that only
trials included in Cochrane reviews would be considered for eligibility.
Eligibility criteria

Cochrane reviews that incorporated RCTs in patients
with axSpA were included in our study. Only reviews
with superiority trials were considered eligible. All reports for each RCT included in eligible reviews were obtained for evaluation. Non-RCTs and trials without full
publications were excluded.

Andreasen et al. Arthritis Research & Therapy

(2020) 22:177

Page 3 of 16

Fig. 1 ASAS/OMERACT core domains for axSpA. Inner circle, core domains for SM-ARD/physical therapy; two inner circles, core domains for
clinical record keeping; all three circles, core domains for DC-ART. SM-ARD, symptom-modifying anti-rheumatic drug; DC-ART, disease-controlling
anti-rheumatic treatment

Risk of bias in individual studies (internal validity)

The risk of bias (RoB) within each study was assessed
using the domains of the RoB tool, as recommended by
the Cochrane Collaboration [8]. The bias domains included selection bias (methods for sequence generation
and allocation concealment), performance bias (blinding
of participants and personnel), attrition bias (incomplete
outcome data), and reporting bias (selective outcome
reporting). Each domain was rated as adequate, inadequate, or unclear risk of bias [9]. RAA completed all
the RoB assessments and applied the RoB that was included and reported in the original Cochrane reviews as
a proxy for a second reviewer assessment.
Data extraction strategy

At trial level, the terms of extraction comprised information
about the first author, publication year, study duration, type
of intervention, and total number of patients randomized.
The domains that were collected included the following:
(i) physical function, (ii) pain, (iii) spinal mobility, (iv)
spinal stiffness, (v) fatigue, (vi) patient’s global assessment,
(vii) peripheral joints/entheses, (viii) acute phase reactants,
and (ix) spine and hip radiographs. Furthermore, at the individual trial level, we extracted data on how many participants achieved the stated primary outcome.
If data on more than one instrument was provided for
any domain, we extracted data on the scale highest on
the list proposed by ASAS/OMERACT [3, 4] (Supplement B).

Trials with multiple intervention arms were treated as
individual trials, referred to as “randomized comparisons” (i.e., three-arm trials with two active interventions
generated two randomized comparisons with placebo).
However, the number of patients in the placebo groups
was divided by the number of active treatment arms,
thus adjusting the standard errors in order to avoid
double counting of patients [10].
Statistical analysis

Treatment effect sizes for all domains were expressed as
standardized mean differences (SMDs) [11]. Standard pairwise meta-analyses for the nine domains’ SMDs with the
corresponding 95% confidence interval (CI) were performed
with Review Manager (version 5.3). Negative SMD values
indicated a beneficial effect of the experimental intervention
(e.g., pain reduction) compared with control comparator; for
ease of interpretation, we used the following “rule of
thumb”: SMDs of more than 0.2 represents a small effect,
0.5 a moderate effect, and 0.8 a large effect [12].
We used standard random-effect meta-analysis as the
default option, whereas the fixed-effect analysis was applied
for the purpose of sensitivity [13]. We used the chi2 test
(Cochrane’s Q test) to assess heterogeneity and the I2
statistic to assess inconsistency [8, 13]. Anticipating
substantial heterogeneity, a pre-specified number of stratified and meta-regression analyses were planned. We conducted the following stratified analyses to examine the
influence of different subgroups—Pharmacological vs. Non-
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pharmacological treatment, and Biologic vs. Other treatment—on the effect of the interventions for all the core
outcomes. Only covariates that reduced the variation (decrease in the τ2 estimated as tau squared [T2]) seen in the
estimates across strata were considered potentially relevant.
In trials where the primary outcome was a composite outcome, meta-regression was performed to investigate which
of the nine core domains (via the available SMDs) were best
associated with the primary composite endpoint of the individual trials (log [ORi]). Meta-regression was performed in
a stepwise manner with the following three steps:
1. Each of the core domains was analyzed as the only
independent variable in a univariate metaregression analysis concerning the effect of the domains on the odds ratio (OR) for achieving the primary endpoint. Arbitrarily, it was decided that
variables with a P value > 0.05 were excluded as potential explanatory variables in step 3. The analyses
were based on all trials reporting the primary
endpoint.
2. The univariate meta-regression analysis mentioned
above was repeated, but only trials reporting all the
domains affecting the log [ORi] (P < 0.05) were included in the analysis.
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3. The explanatory core domains from step 1 (P <
0.05) were analyzed as the independent variables in
a multivariate meta-regression analysis.
These meta-regression analyses enabled us to explore
which core domains were best reflected in the composite
endpoint of axSpA and what is lost when we neglect
core domains by using only one composite outcome
endpoint.
Patient perspective

As part of the author team, MdW—an experienced patient research partner (PRP)—was consulted to review
and elaborate on the protocol and confirmed the importance of the study from the patient’s perspective.
MdW was involved throughout the research process as a
scientific collaborator and voluntarily participated in the
process of designing and preparing the study protocol
and in interpreting results. Where feasible, we followed
the EULAR recommendations for PRPs [14].

Results
Study selection

The search was carried out directly in the Cochrane Library on May 01, 2018. As illustrated in Fig. 2, the

Fig. 2 Flow chart. M0, identified Cochrane reviews; M1, possible eligible reviews; M2, included reviews; K, trials from included Cochrane reviews, k*,
trials included in the evidence synthesis
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inclusion criteria identified twelve Cochrane reviews;
one review was excluded based on the title and abstract
[15]. Eleven reviews were thus retrieved for full-text
examination [16–26]. After full-text examination, we excluded another six reviews (three reviews did not include
axSpA trials [21–23]; two reviews were protocols only
[25, 26]; one review did not report results for axSpA separately [24]). A total of five Cochrane reviews [16–20]
with 85 possible trials were identified for inclusion. We
excluded 35 studies—3 were not RCTs and 32 were not
superiority trials—thus, 50 trials were found eligible for
the qualitative synthesis (for reference list of included
studies, see Supplement B). Of these 50 trials, 7 were
not included in the quantitative synthesis: 6 trials reported most of the data as graphs, and data were not extracted [27–32], and one trial was excluded due to
language restriction (Chinese [33]). The 43 included
RCTs comprised a total of 63 comparisons. The interventions were categorized into three treatment groups:
non-pharmacological (NP) modalities, pharmacological
(P) modalities, and biological (B) modalities.
Study characteristics

The characteristics of the eligible trials are summarized
in Table 1.
Twenty-two trials (42%) used an adequate concealment of allocation and sequence generation (selection).
Twenty-seven trials (54%) were judged to have adequate
blinding of participants and caregivers (performance),
and 34 trials (68%) adequately addressed incomplete
outcome data (attrition). Eight trials [29, 34–40] (16%)
were unable to provide the data of all the pre-specified
outcomes, and we judged them at high risk of selective
outcome reporting bias.
Characteristics of the core outcome measurement set

The outcome matrix (Table 2) shows which core domains were measured for each trial and by which
measurement instrument, differentiating between
those which were fully and partially reported. Overall
outcome reporting was good for SM-ARD/physical
therapy trials; mean (SD) number of ASAS/OMERACT core outcome domains measured for SM-ARD/
physical therapy trials was 4.2 (1.7), and six trials
assessed all five proposed domains. Mean (SD) number of ASAS/OMERACT core outcome domains measured for DC-ART trials was 5.3 (1.8). No DC-ART
trial assessed all nine domains. The most commonly
measured domain was spinal mobility (88%) which
was assessed followed by pain (86%). Most studies
also included measures of physical function (78%),
spinal stiffness (76%), acute phase reactants (70%),
and patient’s global assessment (62%). The instruments used to measure the domains varied widely
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across trials. For the domain fatigue, only seven trials
(14%) had reported this measure separately. Spine radiographs were also poorly represented (2%). None of
the trials reported hip radiographs.
Physical function

All meta-analyses are shown in Supplement B.
A total of 33 RCTs (43 comparisons, 4819 participants) were included in the meta-analysis. As presented in Table 3, the overall analysis of change in
physical function (PF) showed an SMD of − 0.50
(95% CI, − 0.61 to − 0.40), indicating moderate effect
in favor of participants receiving intervention compared to participants receiving control. A high
between-study heterogeneity was observed, τ2 = 0.07,
with substantial inconsistency across studies (I2 =
64%). However, the fixed-effect analysis was in
agreement with the random-effect model, resulting
in a pooled SMD of − 0.53 (− 0.60 to − 0.47). The
stratified meta-analyses for PF did not result in a
significant reduction of τ2; type of intervention did
not seem to be an important factor to the inconsistency observed across axSpA trials, when measuring
change in PF.
Pain

In total, thirty trials (41 intervention comparisons,
4877 participants) were included in the analysis.
Pooled analysis revealed statistically significant reduction in pain with an overall SMD of − 0.48 (−
0.66 to − 0.30), indicating moderate effect across all
interventions in axSpA trials. Between-study inconsistency was substantial (I2 = 62%). A large reduction
in heterogeneity was found in the “type of intervention variable” [58] (i.e., non-pharmacological [58] vs.
pharmacological [P]), which in turn resulted in a
significant reduction in τ2 at 32%, supported by a
statistically highly significant P value (P < 0.001) for
interaction between NP and P. Trials with pharmacological interventions had a pooled SMD of − 0.64
(− 0.78 to − 0.49), whereas trials with NP interventions had an overall SMD of 0.26 (− 0.20 to 0.72).
Spinal mobility

Forty-three trials (45 comparisons, 5091 participants)
were included in our meta-analysis. Pooled analysis revealed a small improvement in spinal mobility (SM) with
an overall SMD of − 0.32 (− 0.48 to − 0.17). A high
between-study heterogeneity was observed, τ2 = 0.21,
with a large inconsistency across studies (I2 = 83%).
None of the subgroup analyses resulted in a significant
reduction in τ2.
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Table 1 Study characteristics and risk of bias assessment of included studies
Author

Year No. of patients No. of patients No. of patients
Trial duration Intervention
randomized
receiving
receiving comparison (weeks)
intervention

Comparator Risk of bias* selection/
performance/attrition/
reporting

Dougados

1986 30

15

15

26

SSZ (P)

PL

A/A/A/A

Feltelius

1986 37

18

19

12

SSZ (P)

PL

U/U/A/A

Nissila

1988 85

43

42

26

SSZ (P)

PL

U/U/A/A

Davis

1989 30

15

15

12

SSZ (P)

PL

U/U/A/A

Kraag

1989 53

26

27

16

Supervised
training (NP)

SC

U/U/I/A

Winkler

1989 63

31

32

24

SSZ (P)

PL

U/U/U/A

Corkill

1990 62

32

30

48

SSZ (P)

PL

A/A/I/A

Krajnc

1990 95

71

24

24

SSZ (P)

PL

U/U/A/A

Taylor

1991 40

20

20

52

SSZ (P)

PL

A/A/A/I

Hidding

1993 144

68

76

36

Group
physiotherapy
(NP)

AC

A/A/I/A

Kirwan

1993 89

44

45

156

SSZ (P)

PL

A/A/A/I

Dougados

1994 70

46

24

12

Ximoprofen 5
mg (P)

PL

A/A/U/A

1994 73

49

24

34

Ximoprofen 10
mg (P)

PL

A/A/U/A

1994 69

45

24

8

Ximoprofen 20
mg (P)

PL

A/A/U/A

1994 74

50

24

6

Ximoprofen 30
mg (P)

PL

A/A/U/A

Clegg

1996 264

131

133

36

SSZ (P)

PL

U/U/A/A

Helliwell

1996 22

15

7

44

In-patient
physiotherapy
(NP)

SC

I/I/I/A

1996 22

15

7

44

Out-patient
hydrotherapy
(NP)

SC

I/I/I/A

1999 148

108

40

6

Piroxicam (P)

PL

U/U/A/A

1999 160

120

40

6

Meloxicam 15
mg (P)

PL

U/U/A/A

1999 164

124

40

6

Meloxicam 22.5
mg (P)

PL

U/U/A/A

2001 51

26

25

52

MTX (P)

AC

U/U/I/I

Dougados

Altan
Dougados

2001 118

80

38

6

Celecoxib (P)

PL

U/U/U/A

2001 128

90

38

6

Ketoprofen (P)

PL

U/U/U/A

Van Tubergen

2001 120

80

40

3

Spa-exercise
therapy (NP)

AC

A/A/I/A

Braun

2002 70

35

35

12

Infliximab (B)

PL

A/A/A/I

Gorman

2002 40

20

20

16

Etanercept (B)

PL

A/A/A/A

Roychowdhury 2002 30

14

16

24

MTX (P)

PL

U/U/A/A

Schmidt

2002 70

34

36

26

SSZ (P)

PL

U/U/U/A

Sweeney

2002 200

100

100

26

Supervised
training (NP)

SC

U/U/I/A

Analay

2003 51

27

24

12

Supervised
training (NP)

SC

A/A/I/A

Brandt

2003 33

16

17

6

Etanercept (B)

PL

A/A/A/I
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Table 1 Study characteristics and risk of bias assessment of included studies (Continued)
Author

Year No. of patients No. of patients No. of patients
Trial duration Intervention
randomized
receiving
receiving comparison (weeks)
intervention

Comparator Risk of bias* selection/
performance/attrition/
reporting

Davis

2003 277

PL

138

139

24

Etanercept (B)

A/A/A/A

Calin

2004 84

45

39

12

Etanercept (B)

PL

U/U/A/A

GonzalezLopez

2004 35

17

18

24

MTX (P)

PL

A/A/A/I

Codish

2005 28

14

14

12

Balneo therapy
(NP)

AC

U/U/I/A

D’Las Penas

2005 40

20

20

16

Supervised
training (NP)

SC

A/A/I/A

Lim

2005 50

25

25

8

Supervised
training (NP)

SC

U/U/I/A

Marzo-Ortega

2005 42

28

14

30

Infliximab (B)

PL

A/A/U/A

Van der Heijde 2005 279

201

78

24

Infliximab (B)

PL

U/U/A/A

Van der Heijde 2005 134

103

31

6

Etoricoxib (P)

PL

A/A/A/A

2005 123

92

31

6

Etoricoxib (P)

PL

A/A/A/A

2005 130

99

31

6

Naproxen (P)

PL

A/A/A/A

Altan

2006 60

30

30

24

Balneo therapy
(NP)

AC

U/U/I/A

Barkhuizen

2006 189

137

52

12

Celecoxib 200
mg (P)

PL

U/U/U/A

2006 213

161

52

12

Celecoxib 400
mg (P)

PL

U/U/U/A

2006 209

157

52

12

Naproxen (P)

PL

U/U/U/A

2006 30

15

15

12

Supervised
training (NP)

SC

U/U/I/A

208

107

24

Adalimumab (B)

PL

A/A/A/A

Ince

Van der Heijde 2006 315
Van der Heijde 2006 180

155

25

24

Etanercept (B)

PL

U/U/U/A

2006 175

150

25

24

Etanercept (B)

PL

U/U/U/A

Lambert

2007 82

38

44

24

Adalimumab (B)

PL

U/U/A/A

Huang

2008 126

83

43

8

Etanercept (B)

PL

U/U/U/U

Inman

2008 177

138

39

14

Golimumab (B)

PL

A/A/A/A

2008 179

149

39

14

Golimumab (B)

PL

A/A/A/A

Barkham

2010 40

20

20

12

Etanercept (B)

PL

U/U/A/A

Inman

2010 76

39

37

12

Infliximab (B)

PL

U/U/U/A

Braun

2011 566

379

187

16

Etanercept (B)

AC

A/A/A/A

Dougados

2011 82

39

43

12

Etanercept (B)

PL

U/U/A/I

NavarroSarabia

2011 108

54

54

12

Etanercept (B)

AC

A/A/A/A

Hu

2012 46

26

20

12

Adalimumab (B)

PL

U/U/U/I

Bao

2014 213

108

105

24

Golimumab (B)

PL

U/U/U/A

Huang

2014 344

229

114

12

Adalimumab (B)

PL

A/A/A/A

*Shown as selection bias (methods for sequence generation and allocation)/performance bias (blinding of participants and personnel)/attrition bias (incomplete
outcome data)/reporting bias (selective outcome reporting). Abbreviations: SSZ sulfasalazine, P pharmacological modalities, PL placebo, NP non-pharmacological
modalities, B biological modalities, SC standard care, AC active comparison, A adequate, U unclear, I inadequate

Spinal stiffness

In total, 25 trials (34 comparisons, 3658 participants) were included in the analysis. The overall effect size revealed substantive statistically significant

improvement in spinal stiffness, SMD of − 0.59 (−
0.74 to − 0.44), indicating moderate effect of all interventions in axSpA trials. The heterogeneity was
large, τ2 = 0.14, with substantial inconsistency
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Table 2 Outcome matrix
Author

Physical function Pain

Spinal mobility

Spinal stiffness Patient’s global Peripheral
assessment
joints/entheses

Acute phase Spine/hip Fatigue
reactants
radiograph

Dougados (1994)
[41]

+,+ (DFI)

+,+
(VAS)

+,+ (Schober)

+,+ (minutes)

−

−

−

−/−

−

Dougados (1999)
[42]

+,+ (DFI)

+,+
(VAS)

+,+ (Schober)

+,+ (minutes)

+,+ (VAS)

−

+,+ (CRP)

−/−

−

Dougados (2001)
[43]

+,+ (BASFI)

+,+
(VAS)

+,+ (Schober)

+,+ (minutes)

+,+ (VAS)

−

+,+ (CRP)

−/−

−

Van der Heijde
(2005_2) [44]

+,+ (BASFI)

+,+
(VAS)

+,+ (Schober)

+,+ (minutes)

+,+ (VAS)

+,+
+,+ (CRP)
(BASDAI question 4)

−/−

−

Barkhuizen (2006) +,+ (BASFI)
[27]

+,+
(VAS)

+,+ (Schober)

+,+ (minutes)

+,+ (VAS)

−

+,+ (CRP)

−/−

−

SM-ARD trials

Physical therapy trials
Kraag (1990) [45]

+,+ (TADLQ)

+,+
(VAS)

+,+ (Schober)

+,+ (TADLQ)

−

−

−

−/−

−

Hidding (1993)
[46]

+,+ (DFI 0)

+,+
(VAS)

+,+ (Schober)

+,+ (VAS)

+,+ (VAS)

+,+
(enthesitis index)

−

−/−

−

Helliwell [31]

−

+,+/−
(VAS)

+,+ (Schober)

+,+/− (VAS)

−

−

−

−/−

−

Van Tubergen
(2001) [47]

+,+ (BASFI)

+,+
(VAS)

−

+,+ (minutes)

+,+ (VAS)

−

−

−/−

−

Sweeney (2002)
[48]

+,+ (BASFI)

+,+
(SES)

−

−

+,+ (BAS-G)

−

−

−/−

−

Analay (2003) [49] +,+ (BASFI)

+,+
(VAS)

+,+ (Schober)

+,+ (minutes)

−

−

−

−/−

−

Codish (2005)
[50]

+,+ (BASFI)

+,+
(VAS)

+,+/−
(Schober)

−

−

−

−

−/−

−

Fernandez-deLas-Penas (2005)
[51]

+,+ (BASFI)

−

+,+ (Schober)

−

−

−

−

−/−

−

Lim [30]

+,+ (BASFI)

+,+/−
(VAS)

+,+ (FFD)

−

−

−

−

−/−

−

Ince (2006) [52]

−

−

+,+ (Schober)

−

−

−

−

−/−

−

Altan (2006) [53]

+,+ (BASFI)

+,+
(VAS)

+,+ (Schober)

+,+ (NRS)

+,+ (NRS)

−

−

−/−

−

Dougados (1986)
[54]

+,+ (DFI)

+,+
(VAS)

+,+ (Schober)

+,+ (minutes)

−

+,+
(enthesitis index)

+,+ (ESR)

−/−

−

Feltelius [28]

−

+,+/−
(VAS)

+,+/−
(Schober)

+,+ (VAS)

+,+ (VAS)

+,+
(enthesitis index)

+,+ (ESR)

−/−

−

Nissila (1988) [55]

−

+,+
(VAS)

+,+ (Schober)

+,+ (minutes)

+,+ (VAS)

+,+ (22-joint count)

+,+ (CRP)

−/−

−

Davis (1989) [56]

−

+,+
(VAS)

+,+ (occiput-to- +,+ (VAS)
wall distance)

−

−

+,+ (CRP)

−/−

−

Winkler (1989)
[57]

−

+,+
(VAS)

+,+ (Schober)

+,+ (VAS)

+,+ (66-joint count)

+,+ (ESR)

−/−

−

Corkill [58]

−

+,+
(VAS)

+,+ (occiput-to- +,+ (VAS)
wall distance)

−

−

+,+ (CRP)

−/−

−

DC-ART trials

+,+ (hours)

Krajnc (1990) [59]

−

−

+,+ (Schober)

−

−

−

−/−

−

Taylor [34]

−

+,+
(VAS)

+,+ (Schober)

+,+ (VAS)

+,+/− (NRS)

+,+/− (joint count)

+,+ (CRP)

+,+/− SIJ
score

−

Kirwan [29]

+,− (HAQ)

+,−
(VAS)

+,+ (Schober)

+,+/− (VAS)

+,– (VAS)

+,+/−
(44-joint count)

−

−/−

−

Clegg (1996) [60]

+,+ (DFI)

+,+
(VAS)

+,+ (Schober)

+,+ (minutes)

+,+/− (NRS)

+,+ (44-joint count)

+,+ (CRP)

−/−

−
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Table 2 Outcome matrix (Continued)
Author

Physical function Pain

Spinal mobility

Spinal stiffness Patient’s global Peripheral
assessment
joints/entheses

Acute phase Spine/hip Fatigue
reactants
radiograph

Altan [35]

+,+ (DFI)

+,+
(VAS)

+,− (Schober)

+,+ (minutes)

+,+ (NRS)

+,+ (enthesitis
index)

+,+ (CRP)

−/−

−

Braun [36]

+,+ (BASFI)

+,+/−
(NRS)

+,+ (BASMI)

+,+/−
(minutes)

+,+ (NRS)

+,+ (44-joint count)

+,+ (CRP)

−/−

+,+/−
(NRS)

Gorman (2002)
[61]

+,+ (BASFI)

+,+/−
(VAS)

+,+ (Schober)

+,+ (minutes)

+,+ (VAS)

+,+ (66-joint count)

+,+ (CRP)

−/−

−

Roychowdhury
(2002) [62]

−

−

+,+ (BASMI)

+,+ (minutes)

−

−

+,+ (CRP)

−/−

−

Schmidt (2002)
[63]

+,+ (DFI)

+,+
(VAS)

+,+ (Schober)

+,+ (minutes)

−

+,+
(enthesitis index)

+,+ (CRP)

−/−

−

Brandt [37]

+,+ (BASFI)

+,+/−
(NRS)

+,+ (BASMI)

+,+/− (NRS)

−

+,+/−
(66-joint count)

+,+/− (CRP)

−/−

+,+/−
(NRS)

Davis (2003) [64]

+,+ (BASFI)

+,+/−
(VAS)

+,+ (Schober)

+,+ (minutes)

+,+ (VAS)

+,– (68-joint count)

+,+ (CRP)

−/−

−

Calin (2004) [65]

+,+ (BASFI 0)

+,+
(VAS)

+,+ (BASMI)

+,+ (minutes)

+,+ (VAS)

+,– (68-joint count)

+,+ (CRP)

−/−

+,+ (VAS)

Gonzalez-Lopez
[38]

+,+ (BASFI)

+,+
(VAS)

−

+,+ (VAS)

+,+ (VAS)

+,+ (44-joint count)

+,− (ESR)

−/−

−

Marzo-Ortega
(2005) [66]

+,+ (BASFI)

+,+
(VAS)

−

+,+ (minutes)

−

+,+
(enthesitis index)

+,− (ESR)

−/−

−

Van der Heijde
(2005_1) [44]

+,+ (BASFI)

+,+
(VAS)

+,+ (BASMI)

−

+,+ (VAS)

+,+
(enthesitis Index)

+,+ (CRP)

−/−

−

Van der Heijde
[32]

+,+ (BASFI)

+,+
(VAS)

+,+ (BASMI)

+,+ (VAS)

+,+ (VAS)

+,+ (44-joint count)

+,+ (CRP)

−/−

−

Van der Heijde
(2006_2) [67]

+,+ (BASFI)

+,+
(VAS)

+,+ (Schober)

+,+ (VAS)

+,+ (VAS)

+,+ (70-joint count)

+,+ (CRP)

−/−

−

Lambert (2007)
[68]

+,+ (BASFI)

+,+
(VAS)

+,+ (BASMI)

+,+ (VAS)

+,+ (VAS)

+,+ (44-joint count)

+,+ (CRP)

−/−

−

Inman (2008) [69] +,+ (BASFI)

+,+
(VAS)

+,+ (BASMI)

+,+ (VAS)

+,+ (VAS)

−

+,+ (CRP)

−/−

+,+
(JESQ)

Barkham (2010)
[70]

−

−

+,+ (VAS)

−

−

–

−/−

−

+,+ (BASFI)

Inman (2010) [71] +,+ (BASFI)

−

+,+ (BASMI)

−

+,+ (BAS-G)

−

+,+ (CRP)

−/−

−

Braun (2011) [72]

+,+ (BASFI)

+,+
(VAS)

+,+ (BASMI)

+,+/− (VAS)

+,+ (VAS)

+,+ (66-joint count)

+,+ (CRP)

−/−

−

Dougados [39]

+,+ (BASFI)

+,+
(VAS)

+,+ (BASMI)

−

+,− (VAS)

−

+,+ (CRP)

−/−

−

Navarro-Sarabia
(2011) [73]

+,+ (BASFI)

+,+
(VAS)

+,+ (BASMI)

−

+,+ (VAS)

+,+ (66-joint count)

+,+ (CRP)

−/−

+,+/−
(VAS)

Hu [40]

+,+ (BASFI)

+,+
(VAS)

−

−

−

−

+,+ (CRP)

−/−

+,+/−
(VAS 0–
10)

Bao (2014) [74]

+,+ (BASFI)

+,+
(VAS)

+,+ (BASMI)

−

−

−

+,+ (CRP)

−/−

+,+
(JESQ)

Huang (2014) [75] +,+ (BASFI)

+,+
(VAS)

+,+ (BASMI)

+,+ (VAS)

+,+ (VAS)

+,+ (44-joint count)

+,+ (CRP)

−/−

–

+,+ indicates that outcome was measured and fully reported
+,+/− indicates that outcome was measured and partially reported (e.g., only the P value is given for the comparison)
+,− indicates that outcome was measured but not reported
− indicates that outcome was not measured
Abbreviations: DFI Dougados functional index, VAS visual analogue scale, NRS numeric range scale, ESR erythrocyte sedimentation rate, CRP C-reactive
protein, BASFI Bath Ankylosing Spondylitis Functional Index, TADLQ Toronto Activity of Daily Living Questionnaire, HAQ Health Assessment
Questionnaire, BASRI Bath Ankylosing Spondylitis Radiology Index, SES Stanford Self-Efficacy Scale, BAS-G Bath Ankylosing Spondylitis Global Index,
BASDAI Bath Ankylosing Disease Activity Index, SPARCC SpondyloArthritis Research Consortium of Canada, JESQ Jenkins Sleep Evaluation Questionnaire
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Table 3 Results of the stratified meta-analyses
SMD

95% CI

I2

Tau2

P for interaction

− 0.50

− 0.61, − 0.40

64%

0.07

–

− 0.53

− 0.57, − 0.45
0.08

0.42

Pharmacological

− 0.53

− 0.64, − 0.42

Non-pharmacological

− 0.40

− 0.74, − 0.05
0.08

0.44

0.28

–

0.19

< 0.001

0.29

0.28

0.21

–

0.19

0.28

0.33

0.65

0.14

–

0.18

0.95

0.16

0.34

0.18

–

0.19

0.15

0.20

0.23

0.06

–

0.00

< 0.001

Variable
All trials, physical function

No. of trials/comparisons
33/43

Fixed-effect model
Intervention

Intervention
Biological treatment

− 0.57

− 0.68, − 0.46

Other treatment

− 0.46

− 0.63, − 0.28

− 0.48

− 0.66, − 0.30

− 0.50

− 0.56, − 0.44

Pharmacological

− 0.64

− 0.78, − 0.49

Non-pharmacological

0.26

− 0.20, 0.72

All trials, pain

30/41

Fixed-effect model

87%

Intervention

Intervention
Biological treatment

− 0.64

− 0.80, − 0-49

Other treatment

− 0.41

− 0.68, − 0.14

− 0.32

− 0.48, − 0.17

− 0.32

− 0.38, − 0.26

Pharmacological

− 0.35

− 0.51, − 0.19

Non-pharmacological

− 0.02

− 0.61, 0.56

All trials, spinal mobility

30/45

Fixed-effect model

83%

Intervention

Intervention
Biological treatment

− 0.31

− 0.47, − 0.15

Other treatment

− 0.28

− 0.52, − 0.03

− 0.59

− 0.74, − 0.44

− 0.61

− 0.68, − 0.54

Pharmacological

− 0.60

− 0.76, − 0.44

Non-pharmacological

− 0.61

− 0.93, − 0.29

All trials, spinal stiffness

25/34

Fixed-effect model

75%

Intervention

Intervention
Biological treatment

− 0.77

− 0.88, − 0.65

Other treatment

− 0.55

− 0.75, − 0.35

− 0.71

− 0.89, − 0.54

− 0.74

− 0.81, − 0.67

Pharmacological

− 0.77

− 0.96, − 0.59

Non-pharmacological

− 0.37

− 0.81, 0.07

All trials, PGA

21/28

Fixed-effect model

83%

Intervention

Intervention
Biological treatment

− 0.84

− 1.09, − 0.60

Other treatment

− 0.60

− 0.87, − 0.34

All trials, PJ/E
Fixed-effect model

15/15

0.05

− 0.11, 0.22

0.00

− 0.08, 0.09

− 0.06

− 0.15, 0.03

Intervention
Pharmacological

68%
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Table 3 Results of the stratified meta-analyses (Continued)
Variable

No. of trials/comparisons

Non-pharmacological

SMD

95% CI

0.99

0.63, 1.35

I2

Intervention
Biological treatment

− 0.10

− 0.20, − 0.01

Other treatment

0.27

− 0.10, 0.64

− 0.51

− 0.70, − 0.32

− 0.62

− 0.69, − 0.55

Pharmacological

− 0.51

− 0.70, − 0.32

Non-pharmacological

–

–

All trials, acute phase reactants

27/31

Fixed-effect model

84%

Intervention

Intervention
Biological treatment

− 0.77

− 1.02, − 0.52

Other treatment

− 0.22

− 0.37, − 0.07

0.96

0.22, 1.69

–

–

Pharmacological

–

–

Non-pharmacological

–

–

0.96

0.22, 1.69

− 0.65

− 0.82, − 0.48

− 0.65

− 0.82, − 0.48

Pharmacological

− 0.65

− 0.82, − 0.48

Non-pharmacological

–

–

All trials, spine radiographs

1/1

Fixed-effect model

Tau2

P for interaction

0.04

0.02

0.22

–

–

–

0.12

0.001

−0.07
–

Intervention

–

–

–

–

0.00

–

–

–

–

–

Intervention
Biological treatment
Other treatment
All trials, fatigue
Fixed-effect model

3/4

Intervention

Intervention
Biological treatment

− 0.65

0%

− 0.82, −0.48

Other treatment
SMD standardized mean difference, CI confidence interval, I2 inconsistency (i.e., the percentage of total variation across studies due to heterogeneity), Tau2 tau
squared is an estimate of the variance of the true effect sizes, PJ/E peripheral joint count/enthesitis index

between studies (I2 = 75%). The pre-specified stratified analyses did not result in a significant reduction
of τ2, and type of intervention did not seem to be
an important factor to the inconsistency observed
across trials when measuring change in SS in axSpA
trials.

Patient’s global assessment

Twenty-one RCTs reported sufficient data to be included in the meta-analysis (28 comparisons, 4031 participants). A significantly pooled moderate effect
favoring intervention with large inconsistency was observed, SMD − 0.71 (− 0.89 to − 0.54) and I2 = 83%.
Stratified analyses did result in a significant reduction of
τ2; the type of intervention did not seem to be an

important factor to the inconsistency observed across
trials when measuring change in PGA in axSpA trials.
Peripheral joints and enthesitis index

Fifteen trials (2334 participants) were included in our
meta-analysis. A high between-study heterogeneity was
observed, τ2 = 0.05, with a substantial inconsistency
across studies (I2 = 68%) [13]. There was no significant
difference in the joint count/enthesitis index after the interventions; the overall SMD was 0.05 (− 0.11 to 0.22). A
large reduction in heterogeneity was found in the “type
of intervention variables” (i.e., NP vs. P treatments and B
vs. other treatment [O]), which in turn resulted in significant reductions in τ2, supported by statistically significant P values for interactions between NP/P and B/O
(P < 0.001 and P = 0.03, respectively). Treatment with a
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biological agent had a small effect on reducing the number of swollen joints in axSpA patients, SMD − 0.10 (−
0.20 to − 0.01).

pre-specified stratified analyses performed with regression models did not influence the variation in the estimates across strata and were not considered relevant.

Acute phase reactants

Association with primary endpoint

Twenty-seven trials (31 comparisons, 3869 participants)
were included in our meta-analysis. The overall analysis
of change in APRs showed a moderate all-in-all effect
for all interventions in axSpA trials, SMD = − 0.51 (−
0.70 to − 0.32), with a large inconsistency (I2 = 84%). A
large reduction in heterogeneity was found in the “type
of intervention variable” (i.e., B vs. O treatments), which
in turn resulted in a significant reduction in τ2 at 45%,
supported by a statistically significant P value (P = 0.001)
for interaction between B and O treatments. Trials with
a biological intervention had a large effect on reducing
APRs, SMD of − 0.77 (− 1.02 to − 0.52), whereas trials
with other treatment interventions (i.e., NSAIDs, MTX,
SSZ, and NP) had an overall small effect, SMD = − 0.22
(− 0.37 to − 0.07).

Overall, 27 trials (39 comparisons) stated explicitly what
the primary endpoint measure was and reported the proportion of participants achieving the primary endpoint.
The most commonly composite primary outcome was
the ASAS 20 response criteria (56%) followed by the
change in BASDAI (37%). Two studies (7%) used a customized composite outcome (e.g., the overall change in
PGA).
In total, 5723 axSpA patients were included in the
meta-analysis. The pooled OR for achieving primary
endpoint was 3.26 (2.58 to 4.13) in favor of participants
receiving experimental intervention compared to participants receiving a control comparator.
Univariate meta-regression analyses based on all trials
(i.e., trials that had a measured composite primary endpoint) indicated that a reduction in pain and APRs and
improvements in PF and PGA were significantly associated with increased odds for achieving primary endpoint,
whereas SM, SS, PJ/E, and fatigue were not (Table 4).
We repeated the meta-regression analysis based on trials
reporting all four domains significantly affecting the OR
for achieving primary endpoint. PF, pain, and PGA were
still significantly associated with the OR for achieving
primary endpoint, whereas APRs proved non-significant.
Multivariable meta-regression analyses showed that PF
did not have a statistically significant explanatory effect
on achieving primary outcome when the following explanatory core outcome domains pain, PGA, and APRs
were added to the model simultaneously. Only reduction
in pain and PGA had a statistically significant effect on

Spine/hip radiographs

Only two of the included trials reported a change in
spine radiographs (SR). One trial reported insufficient
data to be included in the meta-analysis. In total, only
one trial with 32 axSpA patients was included in the
analysis. The effect size was 0.96 (0.22 to 1.6), indicating
SSZ did not have an effect on preventing spinal progression. No trial reported hip radiographs.
Fatigue

Three studies reported sufficient data to be included in
the meta-analysis (4 comparisons, 653 participants). The
overall SMD was − 0.65 (− 0.82 to − 0.48), and no
between-study inconsistency was found (I2 = 0%). The

Table 4 Overview of the impact of core outcome domains on the odds ratio (OR) for achieving primary endpoint per trial
Univariate meta-regression analysis
based on trials reporting primary
endpoint

Univariate meta-regression analysis based on trials
reporting all four domains significantly affecting
primary endpoint** (k = 15)

Multivariable meta-regression analysis based
on trials reporting all four domains significantly
affecting primary endpoint** (k = 15)
OR (95% CI)

P value

Domain

k

OR (95% CI)

P value

OR (95% CI)

P value

Overall*

39

3.26 (2.58, 4.13)

< 0.001

3.72 (2.92, 4.74)

< 0.001

PF

31

2.79 (1.58, 4.90)

0.001

3.9 (1.67, 9.15)

0.005

0.56 (0.27, 1.16)

0.105

Pain

27

2.11 (1.45, 3.06)

< 0.001

5.6 (2.4, 13.15)

0.001

5.19 (2.28, 11.77)

0.001

SM

31

1.20 (0.94, 1.5)

0.142

2.25 (1.27, 3.99)

0.009

1.03 (0.64, 1.68)

0.883

SS

22

1.29 (0.81, 2.06)

0.268

1.88 (0.62, 1.56)

0.227

–

–

PGA

20

2.15 (1.41, 3.30)

0.001

2.58 (1.53, 4.34)

0.002

1.87 (1.14, 3.07)

0.018

PJ/E

10

8.14 (0.36, 186.27)

0.161

16.99 (0.00, 3687

0.403

–

–

APR

23

1.68 (1.05, 2.68)

0.031

1.61 (0.99, 2.63)

0.054

0.86 (0.58, 1.29)

0.381

SR

–

–

–

–

–

–

–

Fatigue

4

2.59 (0.00, 1360)

0.581

–

–

–

–

*Based on trials reporting primary outcome; PF physical function, SM spinal mobility, SS spinal stiffness, APR acute phase reactants, SR spine radiographs
**PF, Pain, PGA, APR
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the OR for achieving primary outcome, regardless of
analysis.

Discussion
This meta-research study aimed to assess the effect of
interventions for axSpA according to each core domain
in the existing ASAS/OMERACT-endorsed core outcome set. The eligible studies reported data only for patients with r-axSpA. The most frequent domains
assessed in the included trials were SM and pain, which
are considered prominent features for axSpA [76]. Overall outcome reporting was surprisingly good for SMARD/physical therapy trials, especially considering that
most of the included studies were published prior to implementation of the COS.
The overall reporting for the included DC-ART trials
was sparse. Surprisingly, none of the trials measured all
the nine proposed domains. Fifteen (30%) of the included studies were published before the COS was suggested by ASAS and endorsed by OMERACT, possibly
explaining the lack of measured domains.
We found that all interventions, both nonpharmacological and pharmacological, when compared
to control, resulted in an overall statistically significant reduction in pain related to axSpA, SS, fatigue,
and APRs and an improvement in PF, SM, and PGA
in axSpA trials. Due to our broad eligibility criteria
where the type of interventions varied greatly among
RCTs, the high between-study heterogeneity observed
was not unexpected. However, type of intervention
did not result in significant change in τ2 for all the
domains. For the domain “PF,” the overall effect size
was moderate regardless of type of intervention. Our
meta-analyses provided evidence that interventions in
axSpA trials did not result in an overall reduction in
swollen peripheral joint count/enthesitis index (PJ/E)
or spinal progression more than placebo. However,
when stratifying on type of interventions, it seemed
that biological treatment had a larger effect on reducing the number of swollen PJ/E. However, one
should be cautious to conclude that biologics are superior to other pharmacologicals for treating inflammation in PJ/E, as our meta-analysis included only a
limited number of trials. Radiographic progression
was measured in only two trials and fully reported in
one. Given that most trials spanned 26 weeks or less,
it is not surprising that they did not measure radiographic progression. MRI is an important imaging
tool to assess axSpA, especially early in the disease
course, before radiographic damage is apparent. Adding magnetic resonance imaging (MRI) to the domain
“spine radiographs” could prove useful, as MRI is
commonly used in short-term axSpA trials [77]. However, there is currently no consensus on how to
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monitor treatment response using MRI modalities in
axSpA patients [78].
For transparency, we believe all domains and instruments used in trials should be reported. We found
that domains and instruments sometimes were used
but not reported separately. For example, the domain
“fatigue,” which is included in the Bath Ankylosing
Spondylitis Disease Activity Index (BASDAI), was
rarely reported separately, whereas the domain “spinal
stiffness,” also included in BASDAI, was reported in
half of all the studies.
As with previous findings, this meta-epidemiological
study found that pain and PGA are important predictors
for treatment responses in axSpA trials [79], thus emphasizing the value of reporting core domains separately.
Outcome reporting bias (ORB) can affect the quality
of evidence within a systematic review and meta-analysis
[80]. We found a high suspicion of selective ORB in
eight (16%) of the individual included RCTs. In most
cases, it was not possible to make a clear judgment on
reporting bias due to the lack of published protocols in
this context. Where protocols were available, there was
no evidence of selective reporting. If a composite outcome (e.g., BASDAI) was reported but no data on any of
the individual core outcome measurements (e.g., fatigue)
were reported, then we judged ORB as low risk; it might
not have been the trialists’ intention to analyze the individual core outcomes separately. If a study reported
some of the outcomes from the composite outcome
measurement, then we judged ORB as a high risk, as it
is likely that all the core outcome measurements were
analyzed but some were not reported because of nonsignificant results. In many of the individual trials, all of
the outcome domains were not mentioned, thereby requiring clinical judgment to decide whether the outcome
of interest was likely to have been measured for a particular trial.
A limitation of this study was that we did not contact
the trialists to determine whether outcomes were measured; many of the studies were published over 15 years
ago, and it would have been difficult to locate the trialists. Another limitation of this study is that our results
are based on axSpA trials included in Cochrane reviews,
and therefore, we did not have control over the literature
searches used. However, Cochrane reviews are known
for the quality of their searches, and we consider the trials included in our study to be representative and our
results to be generalizable. We used the SMDs to metaanalyze outcomes involving the same or similar constructs. We did not include absolute changes and reported in units/percentages of the most common
instruments that the clinicians will understand. However, SMD is more generalizing and can be interpreted
using a general rule of thumb reported by Cohen, in
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which an SMD of 0.2 represents a small effect, an SMD
of 0.5 represents a medium effect, and an SMD of 0.8 or
larger represents a large effect [12].

Conclusions
Although all types of axSpA conditions were eligible, the
analyses were limited to patients with r-axial SpA (AS),
since none of the eligible studies included patients with
non-radiographic axSpA which could be either be perceived as a limitation or simply a consequence of the
axSpA history reflected in the existing Cochrane reviews.
Consistent outcome reporting for DC-ART trials was
poor. The most responsible core domains for achieving
success in meeting the primary objective per trial were
pain and PGA. Our findings support that PGA and pain
give us a more holistic assessment of disease beyond objective measures of spinal inflammation.
Outcome reporting bias and “missing data” could be
reduced by implementing the endorsed ASAS/OMERACT COS of outcomes—and thereby improving the precision of results in meta-analyses.
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